|
2020 Journal Article Prostate-specific membrane antigen PET-CT in patients with high-risk prostate cancer before curative-intent surgery or radiotherapy (proPSMA): a prospective, randomised, multicentre studyHofman, Michael S., Lawrentschuk, Nathan, Francis, Roslyn J., Tang, Colin, Vela, Ian, Thomas, Paul, Rutherford, Natalie, Martin, Jarad M., Frydenberg, Mark, Shakher, Ramdave, Wong, Lih-Ming, Taubman, Kim, Ting Lee, Sze, Hsiao, Edward, Roach, Paul, Nottage, Michelle, Kirkwood, Ian, Hayne, Dickon, Link, Emma, Marusic, Petra, Matera, Anetta, Herschtal, Alan, Iravani, Amir, Hicks, Rodney J., Williams, Scott and Murphy, Declan G. (2020). Prostate-specific membrane antigen PET-CT in patients with high-risk prostate cancer before curative-intent surgery or radiotherapy (proPSMA): a prospective, randomised, multicentre study. The Lancet, 395 (10231), 1208-1216. doi: 10.1016/S0140-6736(20)30314-7 |
|
2020 Journal Article Baseline and post-treatment 18F-fluorocholine PET/CT predicts outcomes in hepatocellular carcinoma following locoregional therapyWallace, Michael C., Sek, Kenny, Francis, Roslyn J., Samuelson, Shaun, Ferguson, John, Tibballs, Jonathan, Asad, Ali, Preen, David B., MacQuillan, Gerry, Garas, George, Adams, Leon A. and Jeffrey, Gary P. (2020). Baseline and post-treatment 18F-fluorocholine PET/CT predicts outcomes in hepatocellular carcinoma following locoregional therapy. Digestive Diseases and Sciences, 65 (2), 647-657. doi: 10.1007/s10620-019-05781-6 |
|
2019 Journal Article TheraP: a randomized phase 2 trial of 177Lu-PSMA-617 theranostic treatment vs cabazitaxel in progressive metastatic castration-resistant prostate cancer (Clinical Trial Protocol ANZUP 1603)Hofman, Michael S., Emmett, Louise, Violet, John, Y. Zhang, Alison, Lawrence, Nicola J., Stockler, Martin, Francis, Roslyn J., Iravani, Amir, Williams, Scott, Azad, Arun, Martin, Andrew, McJannett, Margaret and Davis, Ian D. (2019). TheraP: a randomized phase 2 trial of 177Lu-PSMA-617 theranostic treatment vs cabazitaxel in progressive metastatic castration-resistant prostate cancer (Clinical Trial Protocol ANZUP 1603). BJU International, 124 (S1), 5-13. doi: 10.1111/bju.14876 |
|
2019 Journal Article Comparison between gallium-68 citrate positron emission tomography-computed tomography and gallium-67 citrate scintigraphy for infection imagingSegard, Tatiana, Morandeau, Laurence M. J. A., Dunne, Marina L., Robinson, James O., Murray, Ronan J., Geelhoed, Elizabeth A. and Francis, Roslyn J. (2019). Comparison between gallium-68 citrate positron emission tomography-computed tomography and gallium-67 citrate scintigraphy for infection imaging. Internal Medicine Journal, 49 (8), 1016-1022. doi: 10.1111/imj.14231 |
|
2019 Journal Article Imaging in pleural mesothelioma: a review of the 14th International Conference of the International Mesothelioma Interest GroupArmato, Samuel G., Francis, Roslyn J., Katz, Sharyn I., Ak, Guntulu, Opitz, Isabelle, Gudmundsson, Eyjolfur, Blyth, Kevin G. and Gupta, Ashish (2019). Imaging in pleural mesothelioma: a review of the 14th International Conference of the International Mesothelioma Interest Group. Lung Cancer, 130, 108-114. doi: 10.1016/j.lungcan.2018.11.033 |
|
2018 Journal Article In search of the vulnerable patient or the vulnerable plaque: 18F-sodium fluoride positron emission tomography for cardiovascular risk stratificationBellinge, Jamie W., Francis, Roslyn J., Majeed, Kamran, Watts, Gerald F. and Schultz, Carl J. (2018). In search of the vulnerable patient or the vulnerable plaque: 18F-sodium fluoride positron emission tomography for cardiovascular risk stratification. Journal of Nuclear Cardiology, 25 (5), 1774-1783. doi: 10.1007/s12350-018-1360-2 |
|
2018 Journal Article 68Ga-somatostatin analogue PET-CT: Analysis of costs and benefits in a public hospital settingSegard, Tatiana, Morandeau, Laurence M. J. A., Geelhoed, Elizabeth A and Francis, Roslyn J (2018). 68Ga-somatostatin analogue PET-CT: Analysis of costs and benefits in a public hospital setting. Journal of Medical Imaging and Radiation Oncology, 62 (1), 57-63. doi: 10.1111/1754-9485.12638 |
|
2018 Journal Article The impact of 68 Ga-PSMA PET/CT on management intent in prostate cancer: Results of an australian prospective multicenter studyRoach, Paul J., Francis, Roslyn, Emmett, Louise, Hsiao, Edward, Kneebone, Andrew, Hruby, George, Eade, Thomas, Nguyen, Quoc A., Thompson, Benjamin D., Cusick, Thomas, McCarthy, Michael, Tang, Colin, Ho, Bao, Stricker, Philip D. and Scott, Andrew M. (2018). The impact of 68 Ga-PSMA PET/CT on management intent in prostate cancer: Results of an australian prospective multicenter study . Journal of Nuclear Medicine, 59 (1), 82-88. doi: 10.2967/jnumed.117.197160 |
|
2017 Journal Article Is FCH PET able to identify foci of infection superiorly to FDG PET?Hardy, Liesel Elisabeth, Hessamodini, Hannah, Wallace, Michael and Francis, Roslyn (2017). Is FCH PET able to identify foci of infection superiorly to FDG PET?. BMJ Case Reports, 2017 bcr-2017-219944, 1-1. doi: 10.1136/bcr-2017-219944 |
|
2016 Journal Article A pilot study of the utility of choline PET-CT in prostate cancer biochemical relapse following radical prostatectomyTan, Hendrick, Joseph, David, Loh, Nelson K., McCarthy, Michael, Leong, Eugene, Siew, Teck, Segard, Tatiana, Morandeau, Laurence, Trevenen, Michelle and Francis, Roslyn J. (2016). A pilot study of the utility of choline PET-CT in prostate cancer biochemical relapse following radical prostatectomy. Journal of Medical Imaging and Radiation Oncology, 60 (3), 374-381. doi: 10.1111/1754-9485.12455 |
|
2015 Journal Article A phase 1b clinical trial of the CD40-activating antibody CP-870,893 in combination with cisplatin and pemetrexed in malignant pleural mesotheliomaNowak, A. K., Cook, A. M., McDonnell, A. M., Millward, M. J., Creaney, J., Francis, R. J., Hasani, A., Segal, A., Musk, A. W., Turlach, B. A., McCoy, M. J., Robinson, B. W.S. and Lake, R. A. (2015). A phase 1b clinical trial of the CD40-activating antibody CP-870,893 in combination with cisplatin and pemetrexed in malignant pleural mesothelioma. Annals of Oncology, 26 (12), 2483-2490. doi: 10.1093/annonc/mdv387 |
|
2015 Journal Article Characterization of hypoxia in malignant pleural mesothelioma with FMISO PET-CTFrancis, Roslyn J., Segard, Tatiana, Morandeau, Laurence, Lee, Y.C. Gary, Millward, Michael J., Segal, Amanda and Nowak, Anna K. (2015). Characterization of hypoxia in malignant pleural mesothelioma with FMISO PET-CT. Lung Cancer, 90 (1), 55-60. doi: 10.1016/j.lungcan.2015.07.015 |
|
2015 Journal Article A multicentre comparison of quantitative 90Y PET/CT for dosimetric purposes after radioembolization with resin microspheres: The QUEST Phantom StudyWillowson, Kathy P., Tapner, Michael, The QUEST Investigator Team, , Bailey, Dale L., Willowson, K. P., Tapner, M. J., Ahmadzadehfar, H., Amthauer, H., Großer, O. S., Arbizu, J., Martí-Climent, J. M., Rodriguez-Fraile, M., Attarwala, A. A., Glatting, G., Molina-Duran, F., Bagni, O., Filippi, L., Benard, F., Celler, A., Bonutti, F., Botta, F., Ferrari, M., Boucek, J. A., Francis, R., Bourgeois, A. C., Bradley, Y. C., Pasciak, A. S., Buchholz, H. G., Miederer, M. ... Yu, N. (2015). A multicentre comparison of quantitative 90Y PET/CT for dosimetric purposes after radioembolization with resin microspheres: The QUEST Phantom Study. European Journal of Nuclear Medicine and Molecular Imaging, 42 (8), 1202-1222. doi: 10.1007/s00259-015-3059-9 |
|
2014 Journal Article Interventional therapies for malignant pleural effusions: The present and the futureThomas, Rajesh, Francis, Roslyn, Davies, Helen E. and Gary Lee, Y. C. (2014). Interventional therapies for malignant pleural effusions: The present and the future. Respirology, 19 (6), 809-822. doi: 10.1111/resp.12328 |
|
2014 Journal Article A Gelatin liver phantom of suspended 90Y resin microspheres to simulate the physiologic microsphere biodistribution of a postradioembolization liverKao, Yung Hsiang, Luddington, Oliver S., Culleton, Simone R., Francis, Roslyn J. and Boucek, Jan A. (2014). A Gelatin liver phantom of suspended 90Y resin microspheres to simulate the physiologic microsphere biodistribution of a postradioembolization liver. Journal of Nuclear Medicine Technology, 42 (4), 265-268. doi: 10.2967/jnmt.114.145292 |
|
2014 Journal Article Observer variability in mesothelioma tumor thickness measurements: Defining minimally measurable lesionsArmato III, Samuel G., Nowak, Anna K., Francis, Roslyn J., Kocherginsky, Masha and Byrne, Michael J. (2014). Observer variability in mesothelioma tumor thickness measurements: Defining minimally measurable lesions. Journal of Thoracic Oncology, 9 (8), 1187-1194. doi: 10.1097/JTO.0000000000000211 |
|
2013 Journal Article Mycobacterium mimicking metastatic melanomaTeh, R. W., Feeney, K., Francis, R. J., Phillips, M. and Millward, M. J. (2013). Mycobacterium mimicking metastatic melanoma. Internal Medicine Journal, 43 (12), 1342-1346. doi: 10.1111/imj.12209 |
|
2013 Journal Article Post-radioembolization yttrium-90 PET/CT-part 2: Dose-response and tumor predictive dosimetry for resin microspheresKao, Yung-Hsiang, Steinberg, Jeffrey D., Tay, Young-Soon, Lim, Gabriel K. Y., Yan, Jianhua, Townsend, David W., Budgeon, Charley, Boucek, Jan A., Francis, Roslyn J., Cheo, Timothy S. T., Burgmans, Mark C., Irani, Farah G., Lo, Richard H. G., Tay, Kiang-Hiong, Tan, Bien-Soo, Chow, Pierce K. H., Satchithanantham, Somanesan, Tan, Andrew E. H., Ng, David C. E. and Goh, Anthony S. W. (2013). Post-radioembolization yttrium-90 PET/CT-part 2: Dose-response and tumor predictive dosimetry for resin microspheres. EJNMMI Research, 3 (1), 1-27. doi: 10.1186/2191-219X-3-57 |
|
2013 Journal Article Detection of hypoxia with 18F-fluoromisonidazole ( 18F-FMISO) PET/CT in suspected or proven pancreatic cancerSegard, Tatiana, Robins, Peter D., Yusoff, Ian F., Ee, Hooi, Morandeau, Laurence, Campbell, Elaine M. and Francis, Roslyn J. (2013). Detection of hypoxia with 18F-fluoromisonidazole ( 18F-FMISO) PET/CT in suspected or proven pancreatic cancer. Clinical Nuclear Medicine, 38 (1), 1-6. doi: 10.1097/RLU.0b013e3182708777 |
|
2012 Journal Article A phase ii study of intermittent sunitinib malate as second-line therapy in progressive malignant pleural mesotheliomaNowak, Anna K., Millward, Michael J., Creaney, Jenette, Francis, Roslyn J., Dick, Ian M., Hasani, Arman, Van Der Schaaf, Agatha, Segal, Amanda, Musk, Arthur W. and Byrne, Michael J. (2012). A phase ii study of intermittent sunitinib malate as second-line therapy in progressive malignant pleural mesothelioma. Journal of Thoracic Oncology, 7 (9), 1449-1456. doi: 10.1097/JTO.0b013e31825f22ee |
